Drug Type Antisense oligonucleotides |
Synonyms ARRx, ISIS ARRX, ISIS-ARRx + [8] |
Target |
Mechanism AR antagonists(Androgen Receptor antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 24 Mar 2021 | |
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 24 Mar 2021 | |
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 24 Mar 2021 | |
Prostatic Cancer | Phase 2 | GB | 18 Sep 2016 | |
Solid tumor | Phase 2 | US | - | |
Solid tumor | Phase 2 | GB | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 May 2014 | |
Advanced Malignant Solid Neoplasm | Phase 1 | GB | 01 May 2014 |